Quick Answer
VYNE Therapeutics Inc. reported Revenue (ASC 606) of $570.0 thousand for fiscal year 2025.
VYNE Therapeutics Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $570.0K | +13.8% |
| 2024 | $501.0K | +18.2% |
| 2023 | $424.0K | -11.1% |
| 2022 | $477.0K | -48.8% |
| 2021 | $931.0K | -95.6% |
| 2020 | $20.99M | +4638.8% |
| 2019 | $443.0K | -87.7% |
| 2018 | $3.60M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $69.0K | -65.2% | -65.8% |
| March 31, 2025 | $202.0K | +106.1% | +66.9% |
| September 30, 2024 | $121.0K | +6.1% | -38.9% |
| June 30, 2024 | $198.0K | +46.7% | +102.0% |
| March 31, 2024 | $98.0K | -1.0% | -14.0% |
| September 30, 2023 | $114.0K | -31.7% | -15.6% |
| June 30, 2023 | $135.0K | +7.1% | +36.4% |
| March 31, 2023 | $99.0K | -44.4% | -40.7% |
- VYNE Therapeutics Inc. showed an increase of +13.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2025 period, VYNE Therapeutics Inc.’s revenue (asc 606) has declined by 84.1% (from $3.60 million to $570.0 thousand).
- The most recent figure is from VYNE Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: